328 related articles for article (PubMed ID: 32662532)
1. Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.
San Luciano M; Tanner CM; Meng C; Marras C; Goldman SM; Lang AE; Tolosa E; Schüle B; Langston JW; Brice A; Corvol JC; Goldwurm S; Klein C; Brockman S; Berg D; Brockmann K; Ferreira JJ; Tazir M; Mellick GD; Sue CM; Hasegawa K; Tan EK; Bressman S; Saunders-Pullman R;
Mov Disord; 2020 Oct; 35(10):1755-1764. PubMed ID: 32662532
[TBL] [Abstract][Full Text] [Related]
2. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
[TBL] [Abstract][Full Text] [Related]
3. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.
Kmiecik MJ; Micheletti S; Coker D; Heilbron K; Shi J; Stagaman K; Filshtein Sonmez T; Fontanillas P; Shringarpure S; Wetzel M; Rowbotham HM; Cannon P; Shelton JF; Hinds DA; Tung JY; ; Holmes MV; Aslibekyan S; Norcliffe-Kaufmann L
Brain; 2024 Jun; 147(6):1996-2008. PubMed ID: 38804604
[TBL] [Abstract][Full Text] [Related]
5. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
[TBL] [Abstract][Full Text] [Related]
6. Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease.
Cui SS; Fu R; Du JJ; Lin YQ; Huang P; Gao C; Zhou HY; Chen SD
BMC Neurosci; 2021 Mar; 22(1):22. PubMed ID: 33771108
[TBL] [Abstract][Full Text] [Related]
7. Occupational Pesticide Exposure in Parkinson's Disease Related to GBA and LRRK2 Variants.
Brown EG; Goldman SM; Coffey CS; Siderowf A; Simuni T; Meng C; Brumm MC; Caspell-Garcia C; Marek K; Tanner CM;
J Parkinsons Dis; 2024; 14(4):737-746. PubMed ID: 38820021
[TBL] [Abstract][Full Text] [Related]
8. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
[TBL] [Abstract][Full Text] [Related]
9. Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score.
Iwaki H; Blauwendraat C; Makarious MB; Bandrés-Ciga S; Leonard HL; Gibbs JR; Hernandez DG; Scholz SW; Faghri F; ; Nalls MA; Singleton AB
Mov Disord; 2020 May; 35(5):774-780. PubMed ID: 31958187
[TBL] [Abstract][Full Text] [Related]
10. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
Dzamko N; Rowe DB; Halliday GM
Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
[TBL] [Abstract][Full Text] [Related]
11. Penetrance of Parkinson disease LRRK2 G2385R-associated variant in the Chinese population.
Wang P; Cui P; Luo Q; Chen J; Tang H; Zhang L; Chen S; Ma J
Eur J Neurol; 2022 Sep; 29(9):2639-2644. PubMed ID: 35608967
[TBL] [Abstract][Full Text] [Related]
12. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA; Soto-Ortolaza AI; Heckman MG; Aasly JO; Abahuni N; Annesi G; Bacon JA; Bardien S; Bozi M; Brice A; Brighina L; Van Broeckhoven C; Carr J; Chartier-Harlin MC; Dardiotis E; Dickson DW; Diehl NN; Elbaz A; Ferrarese C; Ferraris A; Fiske B; Gibson JM; Gibson R; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lesage S; Lin CH; Lynch T; Maraganore DM; Mellick GD; Mutez E; Nilsson C; Opala G; Park SS; Puschmann A; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Theuns J; Tomiyama H; Uitti RJ; Valente EM; van de Loo S; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Farrer MJ;
Lancet Neurol; 2011 Oct; 10(10):898-908. PubMed ID: 21885347
[TBL] [Abstract][Full Text] [Related]
13. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
[TBL] [Abstract][Full Text] [Related]
14. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
[TBL] [Abstract][Full Text] [Related]
15. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
[TBL] [Abstract][Full Text] [Related]
16. Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants.
Wang C; Cai Y; Zheng Z; Tang BS; Xu Y; Wang T; Ma J; Chen SD; Langston JW; Tanner CM; Chan P;
Parkinsonism Relat Disord; 2012 Sep; 18(8):958-63. PubMed ID: 22658533
[TBL] [Abstract][Full Text] [Related]
17. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease.
Bakshi R; Macklin EA; Logan R; Zorlu MM; Xia N; Crotty GF; Zhang E; Chen X; Ascherio A; Schwarzschild MA
Ann Neurol; 2019 Apr; 85(4):593-599. PubMed ID: 30761591
[TBL] [Abstract][Full Text] [Related]
18. Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.
Bryant N; Malpeli N; Ziaee J; Blauwendraat C; Liu Z; ; West AB
Hum Mol Genet; 2021 Apr; 30(6):454-466. PubMed ID: 33640967
[TBL] [Abstract][Full Text] [Related]
19. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
Lai D; Alipanahi B; Fontanillas P; Schwantes-An TH; Aasly J; Alcalay RN; Beecham GW; Berg D; Bressman S; Brice A; Brockman K; Clark L; Cookson M; Das S; Van Deerlin V; Follett J; Farrer MJ; Trinh J; Gasser T; Goldwurm S; Gustavsson E; Klein C; Lang AE; Langston JW; Latourelle J; Lynch T; Marder K; Marras C; Martin ER; McLean CY; Mejia-Santana H; Molho E; Myers RH; Nuytemans K; Ozelius L; Payami H; Raymond D; Rogaeva E; Rogers MP; Ross OA; Samii A; Saunders-Pullman R; Schüle B; Schulte C; Scott WK; Tanner C; Tolosa E; Tomkins JE; Vilas D; Trojanowski JQ; ; Uitti R; Vance JM; Visanji NP; Wszolek ZK; Zabetian CP; Mirelman A; Giladi N; Orr Urtreger A; Cannon P; Fiske B; Foroud T
Ann Neurol; 2021 Jul; 90(1):76-88. PubMed ID: 33938021
[TBL] [Abstract][Full Text] [Related]
20. A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease.
Wang P; Pan J; Luo Q; Chen J; Tang H; Chen S; Ma J
Mov Disord; 2022 Aug; 37(8):1767-1772. PubMed ID: 35733392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
